咨询电话：15012456311
咨询电话：15012456311达比加群酯是zui前沿的新一代口服抗凝药物直接凝血酶抑制剂(DTIs)，用于预防非瓣膜性房颤患者的卒中和全身性栓塞。达比加群酯可提供有效的、可预测的、稳定的抗凝效果，同时较少发生药物相互作用，无药物食物相互作用，无需常规进行凝血功能监测或剂量调整。
深圳远扬化学可提供达比加群酯申报所用全套杂质， 进口国产均有销售，随货附CoA证书，HNMR，MS，HPLC图谱，纯度符合申报要求。另外，我司有自主实验室，可提供达比加群酯杂质定制服务，如以上列表无您需要的杂质，我司详询（请点击本页标题下方，进入该公司展台查看我司信息）。
| Dabigatran | 3-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid | C25H25N7O3 | 471.51 |
| Dabigatran Impurity 1 | ethyl 3-(2-(iminomethyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C20H21N5O3 | 379.41 |
| Dabigatran Impurity 2 | 3-(2-(((4-(N-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid | C32H37N7O5 | 599.68 |
| Dabigatran Impurity 3 | ethyl 3-(1-methyl-3-oxo-N-(pyridin-2-yl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamido)propanoate | C20H22N4O4 | 382.41 |
| Dabigatran Impurity 4 | methyl 3-(2-(hydroxymethyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C19H20N4O4 | 368.39 |
| Dabigatran Impurity 5 | 3-(2-(chloromethyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid | C18H17ClN4O3 | 372.81 |
| Dabigatran Impurity 6 | diethyl 3,3'-((2,2'-(oxybis(methylene))bis(1-methyl-1H-benzo[d]imidazole-5,5'-carbonyl))bis(pyridin-2-ylazanediyl))dipropanoate | C40H42N8O7 | 746.32 |
| Dabigatran Impurity 7 | hexyl (imino(4-(((1-methyl-5-(pyridin-2-ylcarbamoyl)-1H-benzo[d]imidazol-2-yl)methyl)amino)phenyl)methyl)carbamate | C29H33N7O3 | 527.62 |
| Dabigatran Impurity 8 | (Z)-3-(2-(((4-(N'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid | C32H37N7O5 | 599.68 |
| Dabigatran Impurity 9 | ethyl 3-(2-(((4-(((hexyloxy)carbonyl)carbamoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C34H40N6O6 | 628.72 |
| Dabigatran Impurity 10 | (Z)-ethyl 3-(2-(((4-(N'-((hexan-2-yloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C34H41N7O5 | 627.73 |
| Dabigatran Impurity 11 | (Z)-ethyl 3-(2-(((4-(N'-((hexan-3-yloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C34H41N7O5 | 627.73 |
| Dabigatran Impurity 12 | ethyl 3-(1,2-dimethyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C20H22N4O3 | 366.41 |
| Dabigatran Impurity 13 | ethyl 3-(1-methyl-2-oxo-N-(pyridin-2-yl)-2,3-dihydro-1H-benzo[d]imidazole-5-carboxamido)propanoate | C19H20N4O4 | 368.39 |
| Dabigatran Impurity 14 | (Z)-ethyl 2-(((4-(N'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-1H-benzo[d]imidazole-5-carboxylate | C26H33N5O4 | 479.57 |
| Dabigatran Impurity 15 | ethyl 3-(2-(((4-cyanophenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C27H26N6O3 | 482.53 |
| Dabigatran Impurity 16 | ethyl 3-(2-(((4-(ethoxy(imino)methyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate hydrochloride | C29H32N6O4·HCl | 565.06 |
| Dabigatran Impurity 17 | (Z)-methyl 3-(2-(((4-(N'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C33H39N7O5 | 613.71 |
| Dabigatran Impurity 18 | (Z)-hexyl (amino(4-(((5-((3-amino-3-oxopropyl)(pyridin-2-yl)carbamoyl)-1-methyl-1H-benzo[d]imidazol-2-yl)methyl)amino)phenyl)methylene)carbamate | C32H38N8O4 | 598.70 |
| Dabigatran Impurity 19 | ethyl 3-(2-(((4-carbamoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate | C27H28N6O4 | 500.55 |
| Dabigatran Impurity 20 | ethyl 3-(2-(((4-carbamimidoylphenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate hydrochloride | C27H29N7O3·HCl | 536.03 |
| Dabigatran Impurity 21 | ethyl 3-(3-amino-4-(methylamino)-N-(pyridin-2-yl)benzamido)propanoate | C18H22N4O3 | 342.39 |
| Dabigatran Impurity 22 | ethyl 3-(3-(2-((4-cyanophenyl)amino)acetamido)-4-(methylamino)-N-(pyridin-2-yl)benzamido)propanoate | C27H28N6O4 | 500.55 |
达比加群酯杂质新药申报用结构式欢迎我司获取~
